OBJECTIVE: To evaluate the long-term effects of drospirenone (DRSP)/ethinylestradiol (EE) alone, metformin alone, and DRSP/EE-metformin on CD4(+)CD28(null) T lymphocytes frequency, a cardiovascular risk marker, in patients with hyperinsulinemic polycystic ovary syndrome (PCOS). DESIGN: Randomized clinical trial. INTERVENTIONS: Ninety three patients with hyperinsulinemic PCOS were age matched and body mass index matched and randomized to receive a 6 months daily treatment with DRSP (3 mg)/EE (0.03 mg), or metformin (1500 mg), or DRSP/EE combined with metformin. MAIN OUTCOME MEASURES: CD4(+)CD28(null) T-cell frequencies. RESULTS: The DRSP/EE and metformin groups did not show any significant change in the CD4(+)CD28(null) frequency compared to the baseline. Interestingly, a statistically significant decrease in CD4(+)CD28(null) frequency occurred after 6 months of DRSP/EE-metformin (median 3-1.5; P < .01). Of note, this statistically significant association was confirmed after adjusting for baseline values in DRSP/EE-metformin group by analysis of covariance (P < .05). CONCLUSIONS: In women with hyperinsulinemic PCOS, combined therapy with DRSP/EE and metformin may reduce cardiovascular risk.

Moro, F., Morciano, A., Tropea, A., Sagnella, F., Palla, C., Scarinci, E., Ciardulli, A., Martinez, D., Familiari, A., Liuzzo, G., Tritarelli, A., Cosentino, N., Niccoli, G., Crea, F., Lanzone, A., Apa, R., Effects of drospirenone-ethinylestradiol and/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial., <<REPRODUCTIVE SCIENCES>>, 2013; 2013 (Dicembre): 1508-1517. [doi:10.1177/1933719113488444] [http://hdl.handle.net/10807/51268]

Effects of drospirenone-ethinylestradiol and/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial.

Tropea, Anna;Sagnella, Francesca;Scarinci, Elisa;Ciardulli, Andrea;Familiari, Alessandra;Liuzzo, Giovanna;Tritarelli, Alessandra;Niccoli, Giampaolo;Crea, Filippo;Lanzone, Antonio;Apa, Rosanna
2013

Abstract

OBJECTIVE: To evaluate the long-term effects of drospirenone (DRSP)/ethinylestradiol (EE) alone, metformin alone, and DRSP/EE-metformin on CD4(+)CD28(null) T lymphocytes frequency, a cardiovascular risk marker, in patients with hyperinsulinemic polycystic ovary syndrome (PCOS). DESIGN: Randomized clinical trial. INTERVENTIONS: Ninety three patients with hyperinsulinemic PCOS were age matched and body mass index matched and randomized to receive a 6 months daily treatment with DRSP (3 mg)/EE (0.03 mg), or metformin (1500 mg), or DRSP/EE combined with metformin. MAIN OUTCOME MEASURES: CD4(+)CD28(null) T-cell frequencies. RESULTS: The DRSP/EE and metformin groups did not show any significant change in the CD4(+)CD28(null) frequency compared to the baseline. Interestingly, a statistically significant decrease in CD4(+)CD28(null) frequency occurred after 6 months of DRSP/EE-metformin (median 3-1.5; P < .01). Of note, this statistically significant association was confirmed after adjusting for baseline values in DRSP/EE-metformin group by analysis of covariance (P < .05). CONCLUSIONS: In women with hyperinsulinemic PCOS, combined therapy with DRSP/EE and metformin may reduce cardiovascular risk.
2013
Inglese
Moro, F., Morciano, A., Tropea, A., Sagnella, F., Palla, C., Scarinci, E., Ciardulli, A., Martinez, D., Familiari, A., Liuzzo, G., Tritarelli, A., Cosentino, N., Niccoli, G., Crea, F., Lanzone, A., Apa, R., Effects of drospirenone-ethinylestradiol and/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial., <<REPRODUCTIVE SCIENCES>>, 2013; 2013 (Dicembre): 1508-1517. [doi:10.1177/1933719113488444] [http://hdl.handle.net/10807/51268]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/51268
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 15
social impact